Oncology and Autoimmune Diseases
Indication——Advanced colorectal cancer
Mechanism of Action
Based on relevant available study data, SY101 has the following advantages in the treatment of advanced colorectal cancer compared with existing EGFR-targeted monoclonal antibodies:
(1) SY101 is a fully-human EGFR-targeted monoclonal antibody, thereby having a low immunogenicity risk;
(2）Good safety along with a low risk of allergic reactions and serious infusion-related reactions as use of SY101 requires no preventive medication with antihistamines and/or corticosteroids for the patient; No risk of severe acne-like rashes or electrolyte disturbance like hypomagnesemia, low drug-related toxicities, and a longer half-life; Confirmed efficacy, and non-inferiority to first-line EGFR targeted monoclonal antibodies that are commercially available in China as indicated by available data.